YAP

Yes-associated protein

YAP (Yes-associated protein) is a transcription co-activator in the Hippo tumor suppressor pathway and controls cell growth, tissue homeostasis and organ size. YAP is inhibited by the kinase Lats, which phosphorylates YAP to induce its cytoplasmic localization and proteasomal degradation. YAP induces gene expression by binding to the TEAD family transcription factors.

The function of YAP in human cancer is complex and could be cell-type-dependent. For instance, YAP could function as a tumor suppressor in some cell types, such as hematological cancers, by inducing apoptosis in response to DNA damage.

YAP Inhibitors, Antagonists, Activators & Modulators

AICAR

(Acadesine; AICA Riboside) Cat. No.: HY-13417

AICAR (Acadesine) is an adenosine analog and a **AMPK** activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an **autophagy**, **YAP** and **mitophagy** inhibitor.



Purity: 99.92%
Clinical Data: Phase 3
Size: 50 mg, 100 mg, 200 mg, 500 mg

AICAR phosphate

(Acadesine phosphate; AICA Riboside phosphate) Cat. No.: HY-13417A

AICAR phosphate (Acadesine phosphate) is an adenosine analog and a **AMPK** activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an **autophagy**, **YAP** and **mitophagy** inhibitor.



Purity: 99.49%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Cytochalasin D

(Zygosporin A; NSC 209835) Cat. No.: HY-N6682

Cytochalasin D (Zygosporin A; NSC 209835) is a potent and cell-permeable inhibitor of actin polymerization derived from fungus, inhibits the G-actin–cofilin interaction by binding to G-actin.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

K-975

Cat. No.: HY-138565

K-975 is a potent, selective and orally active **TEAD** inhibitor, with a strong inhibitory effect against protein-protein interactions between **YAP1/TAZ** and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lats-IN-1

Cat. No.: HY-138489

Lats-IN-1 is a potent and ATP-competitive inhibitor of **Lats1** and **Lats2** kinases. Lats-IN-1 promotes Yap-dependent proliferation in postmitotic mammalian tissues.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML-7 hydrochloride

Cat. No.: HY-15417

ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits **MLCK** (IC_{50}=300 nM). ML-7 hydrochloride also inhibits **YAP/TAZ**.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

MYF-01-37

Cat. No.: HY-139603

MYF-01-37 is a covalent **TEAD** inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PY-60

Cat. No.: HY-141644

PY-60 is a robust and specific activator of **YAP** transcriptional activity that targets **annexin A2 (ANXA2)** with a K_d of 1.4 μM. PY-60 directly binds to ANXA2 and antagonizes its normal cellular function of repressing YAP activity.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Super-TDU

Cat. No.: HY-P1727

Super-TDU is a specific **YAP** antagonist targeting YAP-TEADs interaction. Super-TDU suppresses tumor growth in gastric cancer mouse model.

Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mg

Super-TDU (1-31)

Cat. No.: HY-P1728

Super-TDU (1-31) is a peptide of Super-TDU, which is an inhibitor of **YAP-TEADs**, shows potent anti-tumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Super-TDU (1-31) (TFA)

Cat. No.: HY-P1728A

Super-TDU (1-31) is a peptide of Super-TDU, which is an inhibitor of **YAP-TEADs**, shows potent anti-tumor activity.

Purity: 96.04%
Clinical Data: No Development Reported
Size: 1 mg

Super-TDU TFA

Cat. No.: HY-P1727A

Super-TDU TFA is a specific **YAP** antagonist targeting YAP-TEADs interaction. Super-TDU TFA suppresses tumor growth in gastric cancer mouse model.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TED-347

Cat. No.: HY-125269

TED-347 is a potent, irreversible, covalent and allosteric inhibitor at **YAP-TEAD protein-protein interaction** with an EC_{50} of 5.9 μM for TEAD4Yap1 protein-protein interaction.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Verteporfin

(CL 318952)

Cat. No.: HY-B0146

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a **YAP** inhibitor which disrupts YAP-TEAD interactions.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VT103

Cat. No.: HY-134955

VT103, an analog of VT101, is an orally active and selective **TEAD1** protein palmitoylation inhibitor. VT103 inhibits **YAP/TAZ-TEAD** promoted gene transcription, blocks **TEAD** auto-palmitoylation, and disrupts interaction between **YAP/TAZ** and **TEAD**.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VT107

Cat. No.: HY-134957

VT-107, as an analogous to VT104, is an orally active and potent **pan-TEAD** auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YAP-TEAD-IN-1

Cat. No.: HY-P2244

YAP-TEAD-IN-1 is a potent and competitive inhibitor of **YAP–TEAD interaction** (IC_{50}=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YAP-TEAD-IN-1 TFA

Cat. No.: HY-P2244A

YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of **YAP-TEAD interaction** (IC_{50}=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

YAP/TAZ inhibitor-1

Cat. No.: HY-111429

YAP/TAZ inhibitor-1 is a **YAP/TAZ** inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC_{50} of <0.100 μM in firefly luciferase assay.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg